To further confirm its clinical relevance, we assessed ONECUT2 expression from benign prostate tissues, primary adenocarcinoma and metastatic CRPC tumors in two independent clinical cohorts and a pooled cohort of TCGA and Beltran10. This evidence concerns the gene ONECUT2 and adenocarcinoma.